BNTX - BioNTech SE - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

14.18B

Cash

12.5B

Avg Qtr Burn

N/A

Short % of Float

0.00%

Insider Ownership

65.11%

Institutional Own.

18.18%

Qtr Updated

03/31/23

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
COMIRNATY (BNT162b2) Details COVID-19, Infectious disease	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
BNT316 (ONC-392) Details Non-small cell lung carcinoma, Cancer, Lung cancer	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
BNT113 Details Head and neck cancer, Human papillomavirus	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
BNT111 w/ LIBTAYO (cemiplimab). Details Melanoma	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Autogene cevumeran (BNT122) (RO7198457) Details Solid tumor/s, Colorectal cancer	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Autogene Cevumeran (BNT122) (w/ pembrolizumab) Details Melanoma	Phase 2 Interim update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Autogene cevumeran (BNT122) (w/ with atezolizumab and chemotherapy) Details Solid tumor/s, Pancreatic cancer, Cancer	Phase 2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
BNT-211 Details Solid tumor/s, Cancer	Phase 1/2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
BNT323 (DB-1303) Details Cancer, Solid tumor/s	Phase 1/2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
BNT-167 Details Vaccine, Shingles	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Autogene Cevumeran (BNT122) (w/ atezolizumab) Details Solid tumor/s, Non-small cell lung carcinoma, Bladder cancer, Melanoma	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
BNT-164 Details Vaccine, Tuberculosis	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.